Organon & Co. (OGN) to Release Earnings on Thursday

Organon & Co. (NYSE:OGN - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect Organon & Co. to post earnings of $0.92 per share and revenue of $1.53 billion for the quarter. Organon & Co. has set its FY 2025 guidance at EPS.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Up 0.7 %

Shares of NYSE OGN traded up $0.09 during midday trading on Friday, hitting $12.21. 2,732,148 shares of the company's stock were exchanged, compared to its average volume of 2,716,418. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a twelve month low of $10.45 and a twelve month high of $23.10. The firm's fifty day simple moving average is $13.86 and its 200-day simple moving average is $15.16. The company has a market cap of $3.15 billion, a PE ratio of 3.67, a P/E/G ratio of 0.90 and a beta of 0.73.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 9.17%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is 33.63%.

Wall Street Analyst Weigh In

OGN has been the subject of several research analyst reports. Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. TD Cowen raised Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley cut their price target on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $20.60.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.